Meplazumab for Injection
Sponsors
Tang-Du Hospital, Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd, Xijing Hospital
Conditions
COVID-19Coronavirus Disease 2019 (COVID-19)Covid19Healthy VolunteersMalariaMalaria (Plasmodium Falciparum)Post-COVID-19
Phase 1
Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia
CompletedNCT04275245
Start: 2020-02-03End: 2020-03-09Updated: 2021-04-09
Clinical Study of Meplazumab to Treat With Malaria
WithdrawnNCT04327310
Start: 2023-03-31End: 2024-03-31Updated: 2023-09-21
A Phase I Clinical Trial of Meplazumab in Healthy Volunteer
CompletedNCT04369586
Start: 2020-04-25End: 2020-11-20Updated: 2021-04-09
Phase 2
Study to Assess the Effect of Meplazumab on COVID-19
CompletedNCT04586153
Start: 2021-02-15End: 2022-12-18Updated: 2023-09-15
the Safety and Efficacy of Meplazumab in Patients With COVID-19
CompletedNCT05113784
Start: 2022-01-21End: 2022-10-08Updated: 2023-09-15
Open-Label Study to Assess Meplazumab in Adult Patients Diagnosed with Plasmodium Falciparum
Active, not recruitingNCT06040346
Start: 2024-04-26End: 2025-10-09Target: 60Updated: 2024-10-29
Phase 3
Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19
CompletedNCT05679479
Start: 2024-01-19End: 2024-04-18Updated: 2024-05-28
To Evaluate the Safety and Efficacy of Meplazumab in Treatment of Post-COVID-19
CompletedNCT05813587
Start: 2023-03-23End: 2023-10-26Updated: 2024-05-28